Therefore, the objective of this study was to analyze the clinical and molecular characteristics of a retrospective cohort of patients with EGFR-mutated NSCLC, who received treatment for metastatic disease between January 1, 2016, and December 30, 2022, at our institution. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.